162 related articles for article (PubMed ID: 35770457)
21. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines.
Teruel C; López-San Román A; Bermejo F; Taxonera C; Pérez-Calle JL; Gisbert JP; Martín-Arranz M; Ponferrada A; Van Domselaar M; Algaba A; Estellés J; López-Serrano P; Linares PM; Muriel A
Am J Gastroenterol; 2010 Sep; 105(9):2003-8. PubMed ID: 20700117
[TBL] [Abstract][Full Text] [Related]
23. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease.
Chupin A; Perduca V; Meyer A; Bellanger C; Carbonnel F; Dong C
Aliment Pharmacol Ther; 2020 Oct; 52(8):1289-1297. PubMed ID: 32840893
[TBL] [Abstract][Full Text] [Related]
24. Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Law CCY; Koh D; Bao Y; Jairath V; Narula N
Inflamm Bowel Dis; 2020 Nov; 26(12):1796-1807. PubMed ID: 32047894
[TBL] [Abstract][Full Text] [Related]
25. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Shukla T; Singh S; Tandon P; McCurdy JD
J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
[TBL] [Abstract][Full Text] [Related]
26. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
[TBL] [Abstract][Full Text] [Related]
27. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Aliment Pharmacol Ther; 2013 Feb; 37(4):420-9. PubMed ID: 23240738
[TBL] [Abstract][Full Text] [Related]
28. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Kirchgesner J; Lemaitre M; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
Gastroenterology; 2018 Aug; 155(2):337-346.e10. PubMed ID: 29655835
[TBL] [Abstract][Full Text] [Related]
29. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
30. Birth Outcome of Children Fathered by Men Treated with Systemic Corticosteroids during the Conception Period - A Cohort Study based on Nationwide Data.
Larsen MD; Friedman S; Magnussen B; Nørgård BM
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):133-138. PubMed ID: 28804964
[TBL] [Abstract][Full Text] [Related]
31. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
32. Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Kanis SL; Modderman S; Escher JC; Erler N; Beukers R; de Boer N; Bodelier A; Depla ACTM; Dijkstra G; van Dijk ARM; Gilissen L; Hoentjen F; Jansen JM; Kuyvenhoven J; Mahmmod N; Mallant-Hent RC; van der Meulen-de Jong AE; Noruzi A; Oldenburg B; Oostenbrug LE; Ter Borg PCJ; Pierik M; Romberg-Camps M; Thijs W; West R; de Lima A; van der Woude CJ;
Gut; 2021 Jul; 70(7):1266-1274. PubMed ID: 33046558
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study.
Chaparro M; Verreth A; Lobaton T; Gravito-Soares E; Julsgaard M; Savarino E; Magro F; Biron AI; Lopez-Serrano P; Casanova MJ; Gompertz M; Vitor S; Arroyo M; Pugliese D; Zabana Y; Vicente R; Aguas M; Shitrit BA; Gutierrez A; Doherty GA; Fernandez-Salazar L; Cadilla MJ; Huguet JM; OʼToole A; Stasi E; Marcos MN; Villoria A; Karmiris K; Rahier JF; Rodriguez C; Palomares DM; Fiorino G; Benitez JM; Principi M; Naftali T; Taxonera C; Mantzaris G; Sebkova L; Iade B; Lissner D; Bradley FI; Roman LA; Marin-Jimenez I; Merino O; Sierra M; Van Domselaar M; Caprioli F; Guerra I; Peixe P; Piqueras M; Rodriguez-Lago I; Ber Y; van Hoeve K; Torres P; Gravito-Soares M; Rudbeck-Resdal D; Bartolo O; Peixoto A; Martin G; Armuzzi A; Garre A; Donday MG; de Carpi MFJ; Gisbert JP
Am J Gastroenterol; 2018 Mar; 113(3):396-403. PubMed ID: 29460920
[TBL] [Abstract][Full Text] [Related]
34. Safety of Anti-TNF-Alpha Therapy During Pregnancy on Long-term Outcome of Exposed Children: A Controlled, Multicenter Observation.
Duricova D; Dvorakova E; Hradsky O; Mitrova K; Durilova M; Kozeluhova J; Kohout P; Zarubova K; Bronsky J; Hradska N; Bronska E; Adamcova M; Machkova N; Hruba V; Bortlik M; Lukas M; Malickova K; Lukas M
Inflamm Bowel Dis; 2019 Mar; 25(4):789-796. PubMed ID: 30239799
[TBL] [Abstract][Full Text] [Related]
35. The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study.
Nørgård BM; Friedman S; Kjeldsen J; Nielsen J
Aliment Pharmacol Ther; 2022 Nov; 56(9):1349-1360. PubMed ID: 36031741
[TBL] [Abstract][Full Text] [Related]
36. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study.
Nørgård BM; Nielsen J; Knudsen T; Nielsen RG; Larsen MD; Jølving LR; Kjeldsen J
Br J Clin Pharmacol; 2021 Apr; 87(4):2111-2120. PubMed ID: 33098713
[TBL] [Abstract][Full Text] [Related]
37. Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α.
Park J; Cheon JH
Korean J Intern Med; 2022 Sep; 37(5):895-905. PubMed ID: 35882566
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease.
Lobatón T; Ferrante M; Rutgeerts P; Ballet V; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2015 Aug; 42(4):441-51. PubMed ID: 26104047
[TBL] [Abstract][Full Text] [Related]
39. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.
Meyer A; Semenzato L; Zureik M; Weill A; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2021 Jul; 54(2):160-166. PubMed ID: 34110040
[TBL] [Abstract][Full Text] [Related]
40. Changes in the Long-term Prognosis of Crohn's Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study.
Ye BD; Hong SN; Seo SI; Kim YJ; Cha JM; Rhee KH; Yoon H; Kim YH; Kim KH; Park SY; Jeong SK; Lee JH; Park H; Kim JS; Im JP; Kim SH; Jang J; Kim JH; Suh SO; Kim YK; Park SH; Yang SK;
Gut Liver; 2022 Mar; 16(2):216-227. PubMed ID: 34148870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
